Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: HECTD1

Gene summary for HECTD1

Gene summary.

Gene information	Species	Human
	Gene symbol	HECTD1
	Gene ID	25831
	Gene name	HECT domain E3 ubiquitin protein ligase 1
	Gene Alias	EULIR
	Cytomap	14q12
	Gene Type	protein-coding
	GO ID	GO:0000003
	UniProtAcc	Q9ULT8

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
25831	HECTD1	HTA11_3410_2000001011	Human	Colorectum	AD	1.06e-19	-5.59e-01	0.0155
25831	HECTD1	HTA11_347_2000001011	Human	Colorectum	AD	1.18e-05	4.85e-01	-0.1954
25831	HECTD1	HTA11_3361_2000001011	Human	Colorectum	AD	4.17e-09	-5.29e-01	-0.1207
25831	HECTD1	HTA11_5212_2000001011	Human	Colorectum	AD	6.67e-03	-5.25e-01	-0.2061
25831	HECTD1	HTA11_99999971662_82457	Human	Colorectum	MSS	5.99e-06	-4.19e-01	0.3859
25831	HECTD1	HTA11_99999973899_84307	Human	Colorectum	MSS	1.98e-03	-5.06e-01	0.2585
25831	HECTD1	HTA11_99999974143_84620	Human	Colorectum	MSS	5.90e-08	-4.61e-01	0.3005
25831	HECTD1	F007	Human	Colorectum	FAP	3.76e-04	-3.83e-01	0.1176
25831	HECTD1	A001-C-207	Human	Colorectum	FAP	1.15e-03	-1.84e-01	0.1278
25831	HECTD1	A015-C-203	Human	Colorectum	FAP	3.58e-31	-3.49e-01	-0.1294
25831	HECTD1	A015-C-204	Human	Colorectum	FAP	9.65e-05	-2.46e-01	-0.0228
25831	HECTD1	A014-C-040	Human	Colorectum	FAP	6.94e-05	-3.05e-01	-0.1184
25831	HECTD1	A002-C-201	Human	Colorectum	FAP	1.46e-15	-3.66e-01	0.0324
25831	HECTD1	A002-C-203	Human	Colorectum	FAP	1.05e-06	-1.69e-01	0.2786
25831	HECTD1	A001-C-119	Human	Colorectum	FAP	2.16e-05	-1.45e-01	-0.1557
25831	HECTD1	A001-C-108	Human	Colorectum	FAP	1.47e-19	-1.75e-01	-0.0272
25831	HECTD1	A002-C-205	Human	Colorectum	FAP	6.00e-25	-1.93e-01	-0.1236
25831	HECTD1	A001-C-104	Human	Colorectum	FAP	1.80e-02	-7.51e-02	0.0184
25831	HECTD1	A015-C-005	Human	Colorectum	FAP	1.02e-09	-4.07e-01	-0.0336
25831	HECTD1	A015-C-006	Human	Colorectum	FAP	3.28e-16	-4.08e-01	-0.0994

Page: 1 2 3 4 5 6 7 8 9 10 11

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:003243433	Oral cavity	NEOLP	regulation of proteasomal ubiquitin-dependent protein catabolic process	38/2005	134/18723	1.19e-08	5.70e-07	38
GO:190336433	Oral cavity	NEOLP	positive regulation of cellular protein catabolic process	41/2005	155/18723	2.87e-08	1.22e-06	41
GO:006113632	Oral cavity	NEOLP	regulation of proteasomal protein catabolic process	46/2005	187/18723	4.76e-08	1.95e-06	46
GO:000189231	Oral cavity	NEOLP	embryonic placenta development	27/2005	82/18723	5.12e-08	2.08e-06	27
GO:000020931	Oral cavity	NEOLP	protein polyubiquitination	53/2005	236/18723	1.22e-07	4.38e-06	53
GO:003243632	Oral cavity	NEOLP	positive regulation of proteasomal ubiquitin-dependent protein catabolic process	26/2005	90/18723	1.58e-06	3.89e-05	26
GO:200006032	Oral cavity	NEOLP	positive regulation of ubiquitin-dependent protein catabolic process	29/2005	107/18723	1.72e-06	4.19e-05	29
GO:190313122	Oral cavity	NEOLP	mononuclear cell differentiation	77/2005	426/18723	2.80e-06	6.41e-05	77
GO:007265931	Oral cavity	NEOLP	protein localization to plasma membrane	56/2005	284/18723	4.51e-06	9.60e-05	56
GO:190180031	Oral cavity	NEOLP	positive regulation of proteasomal protein catabolic process	29/2005	114/18723	6.80e-06	1.36e-04	29
GO:190305232	Oral cavity	NEOLP	positive regulation of proteolysis involved in cellular protein catabolic process	32/2005	133/18723	8.26e-06	1.60e-04	32
GO:199077831	Oral cavity	NEOLP	protein localization to cell periphery	62/2005	333/18723	9.84e-06	1.86e-04	62
GO:003009821	Oral cavity	NEOLP	lymphocyte differentiation	66/2005	374/18723	3.08e-05	4.67e-04	66
GO:00485686	Oral cavity	NEOLP	embryonic organ development	71/2005	427/18723	1.12e-04	1.34e-03	71
GO:007053421	Oral cavity	NEOLP	protein K63-linked ubiquitination	16/2005	56/18723	1.80e-04	1.97e-03	16
GO:00032312	Oral cavity	NEOLP	cardiac ventricle development	27/2005	123/18723	2.14e-04	2.27e-03	27
GO:0060840	Oral cavity	NEOLP	artery development	23/2005	100/18723	3.00e-04	2.97e-03	23
GO:00032814	Oral cavity	NEOLP	ventricular septum development	17/2005	71/18723	1.10e-03	8.28e-03	17
GO:000317011	Oral cavity	NEOLP	heart valve development	16/2005	65/18723	1.11e-03	8.33e-03	16
GO:00032053	Oral cavity	NEOLP	cardiac chamber development	30/2005	161/18723	1.78e-03	1.22e-02	30

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

HECTD1

SNV

Missense_Mutation

c.6715N>A

p.Glu2239Lys

p.E2239K

Q9ULT8

protein_coding

tolerated(0.11)

probably_damaging(0.973)

TCGA-A2-A0YK-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cytoxan

HECTD1

SNV

Missense_Mutation

c.140N>G

p.Thr47Arg

p.T47R

Q9ULT8

protein_coding

deleterious(0.01)

benign(0.148)

TCGA-A2-A0YM-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

HECTD1

SNV

Missense_Mutation

c.2228N>G

p.Pro743Arg

p.P743R

Q9ULT8

protein_coding

deleterious(0)

possibly_damaging(0.896)

TCGA-A8-A08P-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Chemotherapy

5-fluorouracil

HECTD1

SNV

Missense_Mutation

c.5992G>C

p.Glu1998Gln

p.E1998Q

Q9ULT8

protein_coding

deleterious(0.01)

benign(0.115)

TCGA-A8-A095-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

5-fluorouracil

HECTD1

SNV

Missense_Mutation

rs755152978

c.3005N>A

p.Arg1002Gln

p.R1002Q

Q9ULT8

protein_coding

deleterious(0)

probably_damaging(0.916)

TCGA-A8-A09W-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Unknown

HECTD1

SNV

Missense_Mutation

rs748524391

c.4411N>T

p.Arg1471Cys

p.R1471C

Q9ULT8

protein_coding

deleterious(0.02)

benign(0.336)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

HECTD1

SNV

Missense_Mutation

c.1259N>T

p.Ala420Val

p.A420V

Q9ULT8

protein_coding

deleterious(0)

probably_damaging(0.982)

TCGA-AO-A0J9-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

cyclophosphamide

HECTD1

SNV

Missense_Mutation

c.1510G>A

p.Glu504Lys

p.E504K

Q9ULT8

protein_coding

tolerated(0.26)

benign(0.009)

TCGA-AR-A0TP-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

doxorubicin

HECTD1

SNV

Missense_Mutation

c.4696C>G

p.Leu1566Val

p.L1566V

Q9ULT8

protein_coding

tolerated(0.29)

probably_damaging(0.931)

TCGA-B6-A0RG-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

HECTD1

SNV

Missense_Mutation

novel

c.3858N>T

p.Trp1286Cys

p.W1286C

Q9ULT8

protein_coding

deleterious(0)

probably_damaging(0.999)

TCGA-BH-A2L8-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cytoxan

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1